Announcements Trials

Browse Landscape

Phase

Status

Completed 10 Terminated 3 Withdrawn 1 Unknown 1 Recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 12 Carcinoma, Non-Small-Cell Lung 4 Hodgkin Disease 3 Triple Negative Breast Neoplasms 2 Rhabdomyosarcoma 2 Recurrence 2 Neoplasms 2 Advanced Breast Cancer 2 Neoplasm Metastasis 1 NSCLC 1 Metastatic HER2-positive Breast Cancer 1 Lung Neoplasms 1 HER2-positive Advanced Breast Cancer 1 HER2-negative Breast Cancer 1 Fludzoparib" and Anti-angiogenic 1 Carcinoma, Squamous Cell 1 Carcinoma, Large Cell 1 Adenocarcinoma 1

Interventions

pembrolizumab 49 Specimen Handling 29 Magnetic Resonance Spectroscopy 25 Biopsy 25 Radiosurgery 17 Gemcitabine 17 Nivolumab 16 Cyclophosphamide 14 Cisplatin 14 Paclitaxel 13 Carboplatin 13 Bevacizumab 13 Leucovorin 11 Irinotecan 11 Fluorouracil 11 Drug Therapy 11 Taxes 10 Radiotherapy 10 Oxaliplatin 10 Capecitabine 10 trastuzumab deruxtecan 9 fludarabine 9 cemiplimab 8 Doxorubicin 8 Cetuximab 8 abemaciclib 7 Trastuzumab 7 Pemetrexed 7 Fulvestrant 7 Docetaxel 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Neoplasm Metastasis × Vinorelbine × Clear all

NCT07007559 2026-06-05

ASPEN-09-03

ALX Oncology Inc.

Phase 2 Recruiting

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡